These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 17376329

  • 1. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
    Macedo A, Araújo A, Melo FC, Nunes G, Cantinho G, Amorin I.
    Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
    Velasco Latrás M, Carreras Coderch L, Antoñanzas Villar F, Coya Viña J, Martín Comín J, Martínez Carderón F, Nieto Martín-Bejarano J, Sáenz Cusí A, Serrano Bermúdez G, Echevarría Icaza A.
    Clin Transl Oncol; 2005 Jun; 7(5):198-204. PubMed ID: 15960931
    [Abstract] [Full Text] [Related]

  • 3. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
    Dolezal J, Vizda J, Odrazka K.
    Urol Int; 2007 Jun; 78(1):50-7. PubMed ID: 17192733
    [Abstract] [Full Text] [Related]

  • 4. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K, Runge R, Kotzerke J.
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [Abstract] [Full Text] [Related]

  • 5. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
    Lam MG, de Klerk JM, Zonnenberg BA.
    J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G.
    Clin Ter; 2009 Jul; 160(3):193-9. PubMed ID: 19756320
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A.
    J Clin Oncol; 2009 May 20; 27(15):2429-35. PubMed ID: 19364971
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
    Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E.
    Support Care Cancer; 2007 Mar 20; 15(3):339-42. PubMed ID: 16967302
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
    Sinzinger H, Weiss K, Hiltunen J.
    Anticancer Res; 2009 Aug 20; 29(8):3393-5. PubMed ID: 19661362
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.
    Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G.
    Eur J Nucl Med Mol Imaging; 2007 Jul 20; 34(7):1023-30. PubMed ID: 17242920
    [Abstract] [Full Text] [Related]

  • 19. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA.
    Eur J Nucl Med Mol Imaging; 2008 Apr 20; 35(4):756-65. PubMed ID: 18157530
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.